BSE Live
Mar 24, 16:01Prev. Close
369.00
Open Price
375.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 24, 15:54Prev. Close
368.75
Open Price
376.65
Bid Price (Qty.)
395.15 (550)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of SMS Pharmaceuticals (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 67.48 | 32.02 | -72.45 | 1.42 | 10.48 | |
| Net CashFlow From Operating Activities | 78.94 | 65.09 | -34.36 | 19.82 | 14.70 | |
| Net Cash Used In Investing Activities | -48.13 | -36.56 | 118.63 | -24.54 | -25.56 | |
| Net Cash Used From Financing Activities | -9.60 | -30.03 | -56.89 | 7.76 | 11.59 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 21.21 | -1.51 | 27.38 | 3.04 | 0.73 | |
| Cash And Cash Equivalents Begin of Year | 8.25 | 9.75 | 9.01 | 5.98 | 5.25 | |
| Cash And Cash Equivalents End Of Year | 29.46 | 8.25 | 36.39 | 9.01 | 5.98 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
24.03.2026
24.03.2026
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth